Calithera Biosciences, Inc.

ACTIVE

343 Oyster Point Blvd Ste 200, 加利福尼亚州圣马特奥县, California, United Stateswww.calithera.comPublic10 employeesEstablished: 2010-06-01$487

Also known as:

cala

calithera biosciences

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2010

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

66.7%

Phase 2

30.0%

Trial Status Distribution

Completed

53.3%

Terminated

36.7%

Withdrawn

10.0%

Clinical Trials

Trials sponsored by this organization (30)

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2

Terminated

interventional

Jul 20227 participants

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2

Terminated

interventional

Jun 20222 participants

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Terminated

observational

Jan 202120 participants

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Phase 1

Completed

interventional

Oct 202030 participants

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Phase 1

Completed

interventional

Sep 202022 participants

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Phase 2

Terminated

interventional

Jul 202040 participants

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Phase 1

Completed

interventional

Jul 202032 participants

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1

Completed

interventional

Jun 201953 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations